Is LPTH a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for LightPath Technologies (LPTH) rests on Germanium substitution is a materials moat, not just a product line: China's germanium export licensing has made the standard infrared lens material scarce and expensive for US and allied defence buyers, with ingot prices setting records after the restrictions took effect. The bear case rests on valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right. Analysts covering it publish targets from $13.00 to $17.00 against a $6.16 share price on November 16, 2026, so even the professionals disagree by 26% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

LPTH key stats

At $6.16 on November 16, 2026, LightPath Technologies (LPTH) has a market cap of $432M.

Market cap
$432M
P/E (forward)
56.0
Price to book
2.9
Beta
1.53

Market cap, P/E and yield are measured at the $6.16 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with LightPath Technologies (LPTH)?

The last two weeks for LightPath Technologies, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • LPTH closed at $6.16 on November 16, 2026, down 23.1% over the past five trading days (from $8.01).
  • On November 10, 2026, LightPath Technologies filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 10, 2026, LightPath Technologies filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 5, 2026, LightPath Technologies filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

LightPath Technologies designs and manufactures precision optics, with a specialty in the infrared. Its historical business was molded aspheric lenses and infrared components built from proprietary BlackDiamond chalcogenide glass, sold to camera makers, industrial customers and defence primes from plants in Orlando, Latvia and China. Three acquisitions changed what the company sells: Visimid brought embedded thermal camera engineering, G5 Infrared (closed February 2025) brought high-performance cooled infrared camera systems with existing programs of record, and the Amorphous Materials asset purchase in January 2026 added chalcogenide glass melting capacity for large-diameter optics. The result is a vertically integrated supplier that owns the glass, the lens, the assembly and, increasingly, the finished camera, which is why assemblies and modules grew to ~$8.4M of the ~$19.1M reported in fiscal third-quarter 2026 revenue. Fiscal 2026, which ended June 30, 2026 and was reported in September, closed with record revenue of ~$71.7M, nearly double the ~$37.2M of fiscal 2025, including ~$21.2M in the fourth quarter (up ~73%). What re-rated the stock is the combination of that mix shift with a supply chain problem elsewhere. China controls most of the world's germanium, the traditional infrared lens material, and its export licensing regime has pushed Western defence programmes to look for substitutes. LightPath is exclusively licensed by the US Department of Defense to manufacture BDNL-4 as a germanium alternative, and G5 has begun producing germanium-free camera variants using BlackDiamond glass. Orders followed: an ~$18.2M infrared camera award, ~$13M of follow-on counter-drone optical assembly orders for delivery into 2027, and several smaller defence qualification orders. Backlog reached ~$110.6M at March 31, 2026, up ~196% from ~$37.4M nine months earlier. More has come since: in September 2026 LightPath won a Department of War prototype agreement to advance germanium alternatives for infrared imaging, and in October it received an additional ~$6.3M follow-on optical assembly order from the same counter-drone supplier. The company is still unprofitable on a GAAP basis and funded that growth with equity, so the investment question is less about whether demand is real and more about the price attached to it. That price has come down sharply: as of October 16, 2026 the stock closed near $7.81, down ~33% year to date and ~38% over three months, though roughly flat over one year.

The bull case: what would have to be true for $17.00

The most optimistic published target on LPTH is $17.00, +176.0% from the $6.16 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Germanium substitution is a materials moat, not just a product line

China's germanium export licensing has made the standard infrared lens material scarce and expensive for US and allied defence buyers, with ingot prices setting records after the restrictions took effect. LightPath melts its own chalcogenide glass and holds an exclusive DoD license for BDNL-4, and BDNL-4 carries a negative thermo-optic coefficient that removes some of the athermalization complexity germanium designs require. G5's first germanium-free cooled camera variants entered production during 2026, which turns a materials position into a qualified system. In September 2026 the company won a Department of War prototype agreement specifically aimed at advancing germanium alternatives for infrared imaging, a direct government endorsement of the materials programme.

2. Backlog conversion and the shift from components to systems

Backlog of ~$110.6M at March 31, 2026 compares with ~$63M of trailing revenue, and much of it is scheduled for delivery through calendar 2026 and 2027. Assemblies and modules revenue grew ~355% year over year in fiscal third-quarter 2026, which matters more than the headline growth rate because finished systems carry higher content per unit than lenses. Gross margin reached ~36% in that quarter against ~29% a year earlier, and adjusted EBITDA has been positive for three consecutive quarters. The June quarter extended the trend: fiscal fourth-quarter 2026 revenue reached ~$21.2M, up ~73% year over year, gross margin for the trailing year was ~36%, and adjusted EPS of $0.01 matched consensus. Analysts expect fiscal 2027 revenue of ~$107M.

3. Counter-drone and border security are the demand end market

The ~$13M of follow-on orders came from a counter-unmanned-aerial-systems and defence systems supplier, and G5's long-range detection products were built for defence, border security and counter-drone use. Ondas Holdings and Unusual Machines also put ~$8.0M of strategic investment into LightPath to support drone-sector work. Programme timing in this market is lumpy, so quarter-to-quarter revenue will not follow a smooth line even if the multi-year direction holds. The same counter-drone customer placed an additional ~$6.3M follow-on optical assembly order in October 2026, and LightPath named photonics and infrared veteran Scott Payette as general manager of G5 Infrared.

4. The balance sheet is funded for the ramp

Cash stood at ~$55.2M on March 31, 2026 against ~$4.9M nine months earlier, with long-term debt close to nil. A June 2026 placement of ~3.57M shares at $14.00 added roughly $47.0M of net proceeds on top of that. Working capital is the practical constraint on a hardware ramp of this shape, since inventory and receivables must be funded ahead of delivery, and the company now has the cash to do it without an immediate return to the market. By June 30, 2026, after the placement, cash stood at ~$93.2M against ~$10.9M of debt, although operating cash flow for fiscal 2026 was still negative at about -$10.2M.

The bear case: what would have to be true for $13.00

The most pessimistic published target is $13.00, +111.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks LightPath Technologies is worth if the risks below bite instead of the drivers above.

Valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right. Dilution history is the second: common shares outstanding went from ~42.9M at June 30, 2025 to ~61.2M at March 31, 2026, and pro forma for the June 2026 placement and Series G preferred conversions the count is closer to ~70M, meaning existing holders funded the growth by giving up roughly a third of the company inside a year. Execution risk is real and concentrated, because three acquisitions in three years must be integrated while a cooled camera family is redesigned onto new glass, and a slipped qualification pushes revenue by quarters rather than weeks. Customer and programme concentration cuts both ways, since single orders of $13M to $18M are large relative to the revenue base and their delivery schedules extend into 2027. On the legal record: Purcell and Lefkowitz issued a shareholder alert in September 2023 saying it was investigating potential breaches of fiduciary duty by the board, which is a law-firm press release rather than a filed complaint, and no securities-fraud class action against the company appears on a docket. Manufacturing exposure in China and Latvia adds tariff, export-control and geopolitical friction to a business whose main selling point is supply chain independence from China.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding LPTH already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on LPTH

4 analysts cover LPTH, with an average target of $15.12 (+145.5% against $6.16) and a split of 4 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the LPTH forecast and price target page.

How is LPTH valued?

Market cap, P/E and dividend yield at today's price are in the LPTH key stats above. The business figures below come from LightPath Technologies's reported results as of October 2026 and change when it next reports.

  • Revenue (fiscal 2026, ended June 30, 2026): ~$71.7M, up ~93% from ~$37.2M
  • Latest quarter (fiscal Q4 2026): revenue ~$21.2M, up ~73%; adjusted EPS $0.01 vs $0.01 consensus
  • Gross / operating margin (TTM): ~36% / ~-5%
  • Net income (fiscal 2026): ~-$20.6M
  • Order backlog: ~$110.6M at March 31, 2026, up ~196% from ~$37.4M at June 30, 2025
  • Cash and debt: ~$93.2M cash and ~$10.9M debt at June 30, 2026
  • Market value and multiple: ~$547M, roughly 7.6x TTM sales; 52-week range ~$5.83 to ~$18.94

As of October 2026: LightPath runs a June fiscal year, and fiscal 2026 results (published in September 2026) closed the year at ~$71.7M of revenue and a ~$20.6M net loss. At about $7.81 on October 16, 2026 the stock trades near 7.6x sales and ~3.7x book, roughly half the multiple of August, and the forward P/E of ~71x rests on analysts' fiscal 2028 EPS estimate of ~$0.11. Management has described a three-pillar strategy targeting in excess of $300M of annual revenue within five years, an ambition rather than guidance that sits far above the ~$107M analysts expect for fiscal 2027; fiscal first-quarter 2027 results are expected around mid-November.

How do you decide if LPTH is a buy?

Whether LPTH is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold LPTH indirectly through an index or sector ETF before adding more.

What would change your mind on LPTH

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Germanium substitution is a materials moat, not just a product line stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the LPTH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LPTH against your real portfolio and see your actual exposure before deciding.

Your questions about LightPath Technologies

Ask Walnut's AI anything about LPTH and see how it fits what you own.

FAQ

Is LPTH a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Germanium substitution is a materials moat, not just a product line, with revenue (fiscal 2026, ended june 30, 2026) at ~$71.7M, up ~93% from ~$37.2M. The bear case rests on valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right. Analysts covering it are spread from $13.00 to $17.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell LPTH?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $13.00, +111.0% from the $6.16 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for LPTH?

+

Germanium substitution is a materials moat, not just a product line. China's germanium export licensing has made the standard infrared lens material scarce and expensive for US and allied defence buyers, with ingot prices setting records after the restrictions took effect. The most optimistic analyst target on LPTH is $17.00, +176.0% from the $6.16 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for LPTH?

+

Valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right. Dilution history is the second: common shares outstanding went from ~42.9M at June 30, 2025 to ~61.2M at March 31, 2026, and pro forma for the June 2026 placement and Series G preferred conversions the count is closer to ~70M, meaning existing holders funded the growth by giving up roughly a third of the company inside a year. Execution risk is real and concentrated, because three acquisitions in three years must be integrated while a cooled camera family is redesigned onto new glass, and a slipped qualification pushes revenue by quarters rather than weeks. Customer and programme concentration cuts both ways, since single orders of $13M to $18M are large relative to the revenue base and their delivery schedules extend into 2027. On the legal record: Purcell and Lefkowitz issued a shareholder alert in September 2023 saying it was investigating potential breaches of fiduciary duty by the board, which is a law-firm press release rather than a filed complaint, and no securities-fraud class action against the company appears on a docket. Manufacturing exposure in China and Latvia adds tariff, export-control and geopolitical friction to a business whose main selling point is supply chain independence from China. The most pessimistic published target is $13.00, +111.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does LightPath Technologies do?

+

LightPath Technologies designs and manufactures precision optics with a specialty in the infrared, increasingly for defence and thermal imaging systems.

What would have to change for LPTH to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Germanium substitution is a materials moat, not just a product line) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (valuation is the first-order risk, and it has already shown how fast it can move: market value fell from roughly $950M to $1.0B in August 2026 to about $547M on October 16, 2026, and even after that drop the stock trades near 7.6x fiscal 2026 revenue of ~$71.7M while reporting a fiscal-year net loss of about $20.6M, so the price still discounts several years of backlog conversion going right) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does LightPath Technologies actually make?

+

Infrared and visible optics, and increasingly the finished systems built from them. The catalogue runs from molded aspheric lenses and BlackDiamond chalcogenide infrared optics through multi-element assemblies to cooled and uncooled thermal camera systems sold under the G5 Infrared and Visimid brands, mostly into defence, border security and industrial imaging.

Why has LPTH re-rated so sharply?

+

Three things stacked. Revenue nearly doubled in fiscal 2026 to ~$71.7M on the G5 and Visimid acquisitions, backlog rose ~196% in nine months to ~$110.6M on named defence awards, and China's germanium export restrictions gave LightPath's germanium-free BlackDiamond glass a supply-chain reason to win Western defence designs. The 52-week range of ~$5.83 to ~$18.94 shows how much of that repriced, and how much has since come back out: the stock closed near $7.81 on October 16, 2026.

Is LightPath profitable?

+

Not on a GAAP basis. Fiscal 2026, which ended June 30, 2026, produced a net loss of ~$20.6M, including ~$4.1M in each of the last two quarters. Adjusted EPS turned slightly positive at $0.01 in fiscal fourth-quarter 2026, matching consensus, and adjusted EBITDA had been positive for several quarters, so the operating trend improved well before the bottom line did. Analysts still expect a small loss for fiscal 2027.

Walnut is informational, not investment advice, and gives no verdict on LPTH. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks